CMS coverage is expected to begin immediately. Pictured: FDA Building/Adobe Stock, Grandbrothers In the summer’s most highly anticipated regulatory decision, the FDA on Thursday greenlit Eisai and Biogen’s Leqembi (lecanemab) as the first anti-amyloid antibody—and the first disease-alteri...
Not only is this a vast investment for the government, private insurers, patients and the healthcare industry as a whole, but it would be put toward a drug that has reached the market based on shaky data. Reviewing the Evidence Aduhelm approved on an accelerated basis in 2021, foc...
Eisai presented the findings on Tuesday at theAlzheimer's Association International Conferencein Philadelphia, the world's largest meeting for dementia research. The results are a first glimpse at what Alzheimer's patients' future could look like on therapies such as Leqembi, which is currently ta...
LEQEMBI’s impact on the disease trajectory is then modeled into an annual per-patient value to the U.S. society based on four components according to the following equation: a) quality-adjusted life-years (QALY) gains compared to SOC; b) willingness-to-pay (WTP) threshold; c) cost ...